Compliance is a product architecture decision.
Every safeguard described below is enforced in the platform's Layer 0 — before any AI processing runs, not audited after the fact.
Phase 1 is deliberately scoped around lower-risk functionality: information organization, administrative workflows, cost and coverage navigation, appointment navigation. We do not perform autonomous diagnosis, autonomous prescribing, autonomous medication changes, or time-critical clinical commands.
We are not claiming blanket FDA exemption. We conduct function-by-function regulatory assessment as capabilities expand, consistent with the FDA's January 2026 Clinical Decision Support guidance.